PetIQ, Inc. (PETQ)
USD 30.98
(-0.03%)
USD 30.98
(-0.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 81.48 Million USD | 66.81% |
| 2022 | 12.58 Million USD | 9.82% |
| 2021 | 48.84 Million USD | 101.33% |
| 2020 | 22.37 Million USD | 35.92% |
| 2019 | 12.42 Million USD | -9.87% |
| 2018 | 19.61 Million USD | 35.35% |
| 2017 | 16.82 Million USD | 214.3% |
| 2016 | 2.64 Million USD | -18.9% |
| 2015 | 4.77 Million USD | 212.66% |
| 2014 | -5.95 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 32.53 Million USD | 3881.28% |
| 2024 Q2 | 36.03 Million USD | 9.69% |
| 2023 Q3 | 33.6 Million USD | 12.48% |
| 2023 Q4 | 12.69 Million USD | -62.21% |
| 2023 FY | - USD | 66.81% |
| 2023 Q2 | 29.87 Million USD | 8.94% |
| 2023 Q1 | 27.42 Million USD | 1577.31% |
| 2022 Q3 | 13.51 Million USD | -33.32% |
| 2022 FY | - USD | 9.82% |
| 2022 Q1 | 18.36 Million USD | 488.41% |
| 2022 Q4 | 1.63 Million USD | -87.91% |
| 2022 Q2 | 20.27 Million USD | 10.38% |
| 2021 Q1 | 19.79 Million USD | 238.2% |
| 2021 Q2 | 24.98 Million USD | 26.2% |
| 2021 Q3 | 6.68 Million USD | -73.25% |
| 2021 Q4 | -4.72 Million USD | -170.77% |
| 2021 FY | - USD | 101.33% |
| 2020 Q3 | 5.86 Million USD | -43.3% |
| 2020 Q2 | 10.34 Million USD | 64.2% |
| 2020 Q1 | 6.29 Million USD | 330.06% |
| 2020 FY | - USD | 35.92% |
| 2020 Q4 | 5.85 Million USD | -0.19% |
| 2019 Q4 | -2.73 Million USD | -194.38% |
| 2019 FY | - USD | -9.87% |
| 2019 Q3 | 2.9 Million USD | -78.38% |
| 2019 Q2 | 13.41 Million USD | 83.91% |
| 2019 Q1 | 7.29 Million USD | 506.24% |
| 2018 FY | - USD | 35.35% |
| 2018 Q1 | -659 Thousand USD | -158.94% |
| 2018 Q2 | 11.69 Million USD | 1873.9% |
| 2018 Q3 | 10.12 Million USD | -13.39% |
| 2018 Q4 | -1.79 Million USD | -117.74% |
| 2017 Q4 | 1.11 Million USD | -37.61% |
| 2017 Q1 | 5.64 Million USD | 330.76% |
| 2017 FY | - USD | 214.3% |
| 2017 Q2 | 7.51 Million USD | 33.14% |
| 2017 Q3 | 1.79 Million USD | -76.15% |
| 2016 Q1 | 2.98 Million USD | 0.0% |
| 2016 Q4 | 1.31 Million USD | 226.82% |
| 2016 Q3 | -1.03 Million USD | -147.43% |
| 2016 Q2 | 2.17 Million USD | -27.08% |
| 2016 FY | - USD | -18.9% |
| 2015 Q1 | 6.56 Million USD | 0.0% |
| 2015 FY | - USD | 212.66% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 154.285% |
| Theratechnologies Inc. | -10.31 Million USD | 890.144% |
| Safety Shot Inc | -12.18 Million USD | 768.73% |
| Cosmos Health Inc. | -17.06 Million USD | 577.593% |
| Cronos Group Inc. | -72.14 Million USD | 212.941% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 108.811% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 325.836% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -126.155% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 2634.502% |
| ProPhase Labs, Inc. | -14.82 Million USD | 649.578% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 1900.796% |
| Dynavax Technologies Corporation | 9.66 Million USD | -743.017% |
| Radius Health, Inc. | 38.31 Million USD | -112.702% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 3566.0% |
| Alvotech | -484.86 Million USD | 116.806% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 2230.677% |
| Alpha Teknova, Inc. | -25.53 Million USD | 419.065% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 151.296% |
| SCYNEXIS, Inc. | 73.47 Million USD | -10.897% |
| Harrow Health, Inc. | 9.72 Million USD | -738.075% |
| Biofrontera Inc. | -18.45 Million USD | 541.587% |
| DURECT Corporation | -24.68 Million USD | 430.117% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 17.073% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 25.461% |
| OptiNose, Inc. | -15.55 Million USD | 623.925% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -210.232% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -6793.909% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 11563.178% |
| SIGA Technologies, Inc. | 84.15 Million USD | 3.177% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -9935.222% |
| Shineco, Inc. | -26.55 Million USD | 406.87% |
| Phibro Animal Health Corporation | 84.6 Million USD | 3.689% |
| Procaps Group S.A. | 104.02 Million USD | 21.668% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 1069.956% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 2352.47% |
| Viatris Inc. | 3.51 Billion USD | 97.683% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 2230.677% |
| Rockwell Medical, Inc. | -4.69 Million USD | 1835.961% |
| Incannex Healthcare Limited | -18.5 Million USD | 540.37% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 8151.976% |
| Tilray Brands, Inc. | -72.84 Million USD | 211.865% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 73.572% |
| Silver Spike Investment Corp. | 7.34 Million USD | -1010.147% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 80.417% |
| Journey Medical Corporation | 1.92 Million USD | -4141.853% |
| Alimera Sciences, Inc. | 7.27 Million USD | -1019.929% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 2034.675% |
| Assertio Holdings, Inc. | -222.44 Million USD | 136.632% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 2141.924% |
| Embecta Corp. | 245.4 Million USD | 66.795% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 506.804% |
| Procaps Group, S.A. | 104.02 Million USD | 21.668% |
| PainReform Ltd. | -9.56 Million USD | 951.562% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 154.643% |
| Hempacco Co., Inc. | -12.77 Million USD | 737.942% |
| Talphera, Inc. | -9.84 Million USD | 927.941% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 49.977% |
| Alvotech | -484.86 Million USD | 116.806% |
| Lantheus Holdings, Inc. | 491 Million USD | 83.404% |
| Kamada Ltd. | 21.53 Million USD | -278.406% |
| Indivior PLC | 66 Million USD | -23.464% |
| Currenc Group, Inc. | -1.9 Million USD | 4387.442% |
| Evoke Pharma, Inc. | -7.29 Million USD | 1217.426% |
| Flora Growth Corp. | -45.87 Million USD | 277.646% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 506.804% |
| Evolus, Inc. | -41.81 Million USD | 294.896% |
| HUTCHMED (China) Limited | 25.52 Million USD | -219.202% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 66.253% |
| Akanda Corp. | -27.73 Million USD | 393.795% |